ライフサイエンスコーパス: glycoform

1 fy the Fc-glycan structures to a homogeneous glycoform.

2 associated with the level of the mature PC1 glycoform.

3 imolar reduction (20%-25%) of the mature PC1 glycoform.

4 at platelet-VWF exists as a distinct natural glycoform.

5 s prepared by chemical synthesis as a single glycoform.

6 lding is largely insensitive to the specific glycoform.

7 has a similar binding avidity as its parent glycoform.

8 es and a representative homogeneous antibody glycoform.

9 dies of glycoproteins and structure of their glycoforms.

10 odies to produce homogeneous intact antibody glycoforms.

11 oforms of IgG1, including doubly fucosylated glycoforms.

12 omplex type, and low amounts of triantennary glycoforms.

13 ction of fully core-fucosylated high-mannose glycoforms.

14 nts with the characterization of 7 different glycoforms.

15 quantify, and determine the impact of major glycoforms.

16 ely related homologue (beta-hLH) as discrete glycoforms.

17 itions allowed profiling of all abundant mAb glycoforms.

18 hesis of GM-CSF aglycone and two homogeneous glycoforms.

19 2/F3, respectively, to improve resolution of glycoforms.

20 for different cellular cofactors and PrP(C) glycoforms.

21 st, only mild effects were observed for CD45 glycoforms.

22 hia coli that is tolerant to a wide range of glycoforms.

23 C-SIGN tetramer was similar for all antibody glycoforms.

24 glycosylation profile toward agalactosylated glycoforms.

25 are required for the characterization of the glycoforms.

26 m that can be further transformed into other glycoforms.

27 ical synthesis contains discrete homogeneous glycoforms.

28 n a given site are heterogeneous mixtures of glycoforms.

29 now addresses previously refractory antibody glycoforms.

30 ormation of the corresponding homogeneous Fc glycoforms.

31 peptides and HILIC for resolution of peptide glycoforms.

32 or binding of an array of homogeneous IgG-Fc glycoforms.

33 e glycoform as of the production of multiple glycoforms.

34 glycoforms more strongly than Man5 and Man6 glycoforms.

35 osylation comprising high mannose to complex glycoforms.

36 y of the relative quantitation of individual glycoforms.

37 cross a broad range of tumor-associated MUC1 glycoforms.

38 c approaches for heart failure using peptide glycoforms.

39 forms that are difficult to separate in pure glycoforms.

40 ng between bacteria carrying different pilin glycoforms.

41 entification of both targeted and unexpected glycoforms.

42 ylation but may differ in its exact range of glycoforms.

43 (essentially) random combinations of monomer glycoforms; (4) native top-down sequence analysis of the

44 y expressed as a combination of isoforms and glycoforms after proteolytic removal of N- and C-termina

45 ct, or whether the presence of aberrant IgA1 glycoforms alone can produce IgAN.

46 h are isolated as highly complex mixtures of glycoforms, alpha-hGPH obtained by chemical synthesis co

47 ease core fucosylation and induce additional glycoform alterations on hepatocyte proteins.

48 nowledged in Remsima regulatory filings, our glycoform analysis and receptor binding results appear t

49 ve sequence coverage, glycosite mapping, and glycoform analysis of recombinant human mucins by mass s

50 prehensive analytical workflow for IgA1 HR O-glycoform analysis.

51 T, while the synthetic Man(9)GlcNAc(2)-RNase glycoform and natural RNase B did not show CRT-binding a

52 The relative amounts of each glycoform and total site occupancy were quantified using

53 was investigated using native Skp1 acceptor glycoforms and a novel synthetic peptide containing GlcN

54 ich proved the presence of a large number of glycoforms and an unpredicted diversity of the ceramide

55 s in the glycocalyx associated with specific glycoforms and glycoconjugates can be monitored with qua

56 The ability to quantitate individual glycoforms and glycoconjugates will find utility in a br

57 e of naturally occurring coagulation protein glycoforms and inherited defects in carbohydrate attachm

58 orms for binding to four different FcalphaRI glycoforms and investigated the thermodynamics and kinet

59 th supporting MS2 evidence, of under-sampled glycoforms and of those that failed to be identified by

60 timized CID fragmentation enables DIA of IgG glycoforms and suggest that such workflow may enable qua

61 antigen responses for fucosylated bisecting glycoforms and the subsequent association with MUC16 sug

62 The observed glycoforms and their distribution compared favorably to

63 ogonal experimental measurements of N-linked glycoforms and total oxidation.

64 Among the most distinctive features of the glycoforms are (i) a dimethylated rhamnose as the cappin

65 y biological activities of plant-derived SM6 glycoforms are comparable to the human-cell-derived coun

66 Structurally well-defined IgG-Fc glycoforms are highly demanded for understanding the eff

67 lycosylated signaling peptides with multiple glycoforms are identified, including the first report of

68 s, while O-acetylated sialic acid-containing glycoforms are retained longer.

69 ructure information to discriminate isomeric glycoforms are well acknowledged practical problems to b

70 onformation of multiple antigens by a single glycoform as of the production of multiple glycoforms.

71 lycosylation, we aimed to define the natural glycoforms associated with robust Fc-mediated antiviral

72 itates the differential analysis of distinct glycoforms associated with specific proteins at distinct

73 The stochastic distribution of glycoforms at glycosylation sites is revealed.

74 lysis reveals the stochastic distribution of glycoforms at occupied sequons, and the latter provides

75 The efficient identification of these glycoforms at the glycopeptide level by mass spectrometr

76 e observed the highest microheterogeneity of glycoforms at the N187 site of HPX, absence of core fuco

77 ing due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macro

78 press E-selectin ligands, but express a CD44 glycoform bearing alpha-2,3-sialyl modifications.

79 Comparison of 18 glycoforms bearing monosaccharides at Tyr(4) and Tyr(4')

80 ffects of rebuilding this fence with smaller glycoforms by expressing HIV-1 pseudovirions from a prim

81 e glycomic profile in many subtle ways: some glycoforms can be upregulated, some downregulated, some

82 Interestingly, the Fc glycoforms carrying an unusual bisecting sugar moiety su

83 s characterized individually, with about 500 glycoforms characterized per Env protein.

84 igands, the P-selectin glycoprotein ligand-1 glycoform "CLA," and CD43.

85 he expected changes in the quantity of major glycoforms compared to healthy controls.

86 CCS increments that correspond to changes in glycoform compositions.

87 both pharmaceutical proteins, with estimated glycoform concentrations analyzed ranging from 0.35 to 9

88 TN17, which expresses a deeply truncated LPS glycoform consisting of only two 3-deoxy-d-manno-octulos

89 The most abundant glycoform consists of nine neutral monosaccharide residu

90 experimental data for the identification of glycoforms contributing to disease.

91 analysis of glycan data in order to identify glycoforms contributing to disease.

92 ith FcgammaR-expressing cell lines, all 2G12 glycoforms demonstrated similar binding to FcgammaRI, Fc

93 In contrast, two glycoforms derived from glycoengineered plants that lack

94 model, and find that an alpha2-3 sialylated glycoform designed to eliminate uptake by the mannose 6-

95 antitative yields and conserve the number of glycoforms detected.

96 ated by comparing the abundance of different glycoforms determined by mass spectrometry to that deter

97 When closely related glycoforms did not occur naturally, exoglycosidases were

98 These glycoforms differ from what has been reported so far in

99 In human cells, the constituent glycoforms differ mostly in numerous ways of extensions

100 structural basis for immunochemically based glycoform differences, we characterized the O-linked gly

101 oforms of RPTPzeta/phosphacan and that these glycoforms differentially decorate the surface of distin

102 photophysical properties of An-BA to improve glycoform differentiation.

103 uire the ability to target these transferrin glycoforms differently after preloading with exogenously

104 transitions which allowed us to quantify the glycoforms directly in plasma or serum without fractiona

105 ese hormones are administered as mixtures of glycoforms due to limitations of biological methods in p

106 ancy of each glycosylation site by different glycoforms during biological or pathological processes.

107 ymes, resulting in heterogeneous mixtures of glycoforms, each with a distinct physiological activity.

108 version with typical heterogenous mammalian glycoforms (ED(50) = 11 mug) had similar potency to the

109 Extracted ion chromatograms of isomeric glycoforms enabled quantitative assignment of Gd sites.

110 The presence of glycoform families that differ only in branching and/or

111 r nucleotide substrates and appropriate Skp1 glycoforms, followed by chromatographic analysis of acid

112 ses and lead to the exploration of promising glycoforms for antibody therapeutics.Post-translational

113 r modeling, we probed distinct IgA1 and IgA2 glycoforms for binding to four different FcalphaRI glyco

114 Importantly, we identified more than 25 glycoforms for each product and observed glycoform popul

115 ool to guide the engineering of specific Env glycoforms for HIV vaccine design.

116 site-specific quantitative comparison of the glycoforms for two therapeutic enzymes (Cerezyme and VPR

117 has led to the development of specific drug glycoforms, for example, monoclonal antibodies, with enh

118 hose that bind to the periostin protein with glycoforms found in non-malignant cell types.

119 ing three different dissociation methods, 23 glycoforms from all 5 corresponding glycopeptides were i

120 We purified alpha- and beta-antithrombin glycoforms from plasma of 2 homozygous L99F patients.

121 e bovine serum albumin coupled with a common glycoform (fucosylated glycan lacking the alpha1,3-linke

122 Interestingly, the galactose-masked glycoform Gal(1)Glc(1)Man(9)GlcNAc(2)-RNase also showed

123 The synthesis of a selectively modified glycoform Gal(1)Glc(1)Man(9)GlcNAc(2)-RNase was accompli

124 k to develop a synthetic route toward single-glycoform GM-CSF.

125 All of the glycoforms had similar binding to HER2/neu expressed on

126 Quantification of glycoform has previously been demonstrated using a multi

127 further clarified the roles of CD44 and its glycoform HCELL in hematopoietic processes, providing ke

128 00-kDa band, exclusively comprising the CD44 glycoform "HCELL." E-Ig reactivity was most prominent on

129 The data suggested a role for Env glycoform heterogeneity in the activation of the lineage

130 ifferences between laboratories and improved glycoform identification by our laboratory using a pepti

131 Glycosylation is heterogeneous, with twelve glycoforms identified at six of the sites.

132 osidase gave the Glc(1)Man(9)GlcNAc(2)-RNase glycoform in excellent yield.

133 combinant human erythropoietin, revealing 74 glycoforms in a 60-min run.

134 ties for functional studies of these protein glycoforms in different cells and tissues.

135 quantification result uncovers five abundant glycoforms in HCC, including 3 core-fucosylated (CF) for

136 nable identification of pathogenic IgA1 HR O-glycoforms in IgAN.

137 rential, effects of 1 were observed for CD43 glycoforms in multiple hematopoietic cells.

138 valuable for identifying the different KCNE1 glycoforms in native cells and determining the roles N-

139 SWATH data independent quantification of IgG glycoforms in pooled plasma samples of patients with liv

140 howed decreased levels of biofilm-associated glycoforms in the NTHI 86-028NP luxS strain.

141 ne resulted in production of the Man5GlcNAc2 glycoforms, in which more than 50% were core-fucosylated

142 ization of underivatized neutral and anionic glycoforms including oligomannosidic glycan anomers, sia

143 d G2F glycoforms to well-defined homogeneous glycoforms, including a fully sialylated (S2G2F) glycofo

144 Moreover, the galectin-3-bound glycoform increased in cancer, suggesting a pathophysiol

145 as used as a substrate, recruitment of three glycoforms into PrP(Sc) was found to be proportional to

146 nd industry because no apparent bias for any glycoforms is observed.

147 hly desirable; resolution of the fucosylated glycoforms is of particular interest due to their biolog

148 alteration of glycosylation, especially the glycoforms, is crucial and beneficial to improving our u

149 N-linked glycosylation, featuring various glycoforms, is one of the most common and complex protei

150 e reduced heparin affinity of the alpha-L99F glycoform (K(D), 107.9 +/- 3nM) was restored in the beta

151 107.9 +/- 3nM) was restored in the beta-L99F glycoform (K(D), 53.9 +/- 5nM) to values close to the ac

152 Consistent with this finding, 2G12 glycoforms lacking core fucose (and xylose) mediated hig

153 nt with this finding, plant-derived H10-03-6 glycoforms lacking core N-glycan residues mediated highe

154 ate as 7 ppm with baseline resolution at the glycoform level for intact antibodies.

155 ing assay indicated that the synthetic RNase glycoforms maintained essentially the same global confor

156 A binds certain Man7, Man8, and Man9 RNase B glycoforms more strongly than Man5 and Man6 glycoforms.

157 relative abundance of individual fucosylated glycoforms normalized to the level of their nonfucosylat

158 characterize for the first time the T and Tn glycoform O-glycoproteome of the Drosophila melanogaster

159 Interestingly, the new triantennary glycan glycoform of antibody showed much higher affinity for ga

160 We speculated that the natural beta-glycoform of antithrombin might compensate for the effec

161 16D10 was raised against a pathological onco-glycoform of bile salt-dependent lipase isolated from th

162 Therefore, the mature glycoform of CASQ (GlcNAc(2)Man(1-4)) within the SR can

163 The major glycoform of CASQ (GlcNAc(2)Man(9)) found in the proxima

164 gnaling reporter, we quantified the core-2 O-glycoform of CD43 in multiple T cell subsets during graf

165 These findings establish that the HCELL glycoform of CD44 confers tropism to bone and unveil a r

166 , human HSPCs uniquely display a specialized glycoform of CD44 known as hematopoietic cell E-/L-selec

167 monoclonal antibody IIH6, which recognizes a glycoform of dystroglycan, also detects the zebrafish pr

168 the homogeneous core-fucosylated Man5GlcNAc2 glycoform of EPO in the FUT8-overexpressed HEK293S GnT I

169 , depends on a specific alpha-2,6-sialylated glycoform of IgG Fc to induce Interleukin 4 (IL-4) and S

170 a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical mod

171 d a CAR that recognized cancer-associated Tn glycoform of MUC1, a neoantigen expressed in a variety o

172 and binds primarily to the highly acetylated glycoform of PNAG but is not protective against infectio

173 We also identified an O-glycoform of proANP naturally occurring in human circula

174 messenger RNA and protein, and the "mature" glycoform of sIgM.

175 We show here that the gastric glycoform of TFF2 is a calcium-independent lectin, which

176 sal barriers, has elevated binding to the G0 glycoform of the Fc portion of IgG.

177 show that this novel E-selectin ligand is a glycoform of the heavy chain component of the enzyme mye

178 hat the outer arm fucosylation of the A2G2F1 glycoform of the VDKDLQSLEDILHQVENK peptide of fibrinoge

179 arm and total fucosylation of 12 fucosylated glycoforms of 9 glycopeptides in 7 plasma proteins.

180 For the glycoforms of a given glycopeptide or set of derivatized

181 tion time and organ distribution of selected glycoforms of alpha-galactosidase A in a Fabry disease m

182 Eight glycoforms of an O-linked glycopeptide from Nucleobindin

183 esized structurally well-defined homogeneous glycoforms of antibodies with different combinations of

184 a promising platform to produce homogeneous glycoforms of antibodies, but the broad application of t

185 models and promotes the turnover of immature glycoforms of BCR subunits, reducing total cellular BCR

186 HCC patients, comprised of 23 heterogeneous glycoforms of bi- and triantennary, core and terminal fu

187 oenzymatic synthesis of the monoglucosylated glycoforms of bovine ribonuclease (RNase) as specific li

188 engineered plants to generate four different glycoforms of H10-03-6, an Fcab with engineered HER2/neu

189 ation of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms

190 glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) direct

191 w for quantitative analysis of site specific glycoforms of IgG based on data independent acquisition

192 MS methods for the analysis of site specific glycoforms of IgG.

193 of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 gly

194 nd we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycofo

195 ng various homogeneous, natural or synthetic glycoforms of IgG1-Fc for structure-function relationshi

196 ms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples o

197 Linear trendlines were observed for the glycoforms of individual N-linked glycopeptides, the deg

198 highly selective manner to tumor-associated glycoforms of MUC1.

199 the tumor-specific glycosylation present on glycoforms of periostin containing bisecting N-glycans i

200 lonal animal antibody raised to deacetylated glycoforms of PNAG and a fully human IgG1 monoclonal ant

201 dy that both bind to native and deacetylated glycoforms of PNAG mediated complement-dependent opsonic

202 and features quantitative yield, homogeneous glycoforms of produced antibodies and ADCs, compatibilit

203 Quantitative analysis of site specific glycoforms of proteins is technically challenging but hi

204 ive analysis of site- and structure-specific glycoforms of proteins.

205 chment, leading to the formation of multiple glycoforms of proteins.

206 achieved and what involvement the different glycoforms of PrP have in these processes remain to be d

207 ty of polydopamine-immobilized Con A for the glycoforms of RNase B is significantly affected by sligh

208 ese antibodies define biochemically distinct glycoforms of RPTPzeta/phosphacan and that these glycofo

209 t instrumentation to the characterization of glycoforms of rt-PA.

210 Modulated glycoforms of sIgM are signal competent and could bind t

211 The immature glycoforms of SLC26A9 and CFTR co-immunoprecipitated, co

212 Additionally, glycoforms of the antibody charge variants were identifi

213 We have generated five different glycoforms of the broadly HIV-1-neutralizing mAb 2G12 in

214 with these N-glycopeptides, 53 compositional glycoforms of the hinge region O-glycopeptide were profi

215 in the production of fully core-fucosylated glycoforms of the oligomannose substrate Man5GlcNAc2, su

216 The glycoforms of the same parent peptide were also chromato

217 Here we have generated 3D structures of glycoforms of the spike (S) glycoprotein from SARS-CoV-2

218 We expressed different glycoforms of the Spike-protein and ACE2 in CRISPR-Cas9

219 ing, the binding of galectin-3 to particular glycoforms of transferrin.

220 plasmon resonance chip that captures native glycoforms of two well known E-selectin ligands (CD44/he

221 lar dynamics simulations of various Asn(347) glycoforms of uncleaved CBG indicated that multiple Asn(

222 h uniform glycosylation and a higher potency glycoform offer promise as biodefense therapeutics.

223 ing live cells, we converted the native CD44 glycoform on MSCs into hematopoietic cell E-selectin/L-s

224 Furthermore, no significant impact from the glycoform on the ionization properties of the glycopepti

225 It will also discuss how regulating N-glycoforms on the endothelial surface may allow for the

226 Distinct glycoforms on the IgG crystallizable fragment (Fc) dicta

227 In addition to 12 novel AFP glycoforms, our quantification result uncovers five abun

228 n-beta allowed the assignment of at least 18 glycoforms, plus a variety of deamidation, succinimide,

229 25 glycoforms for each product and observed glycoform population differences, with afucosylated glyc

230 aightforwardly discriminate between distinct glycoform populations.

231 nable deep characterization of heterogeneous glycoform populations.

232 mucin-selective binding agents with retained glycoform preferences.

233 High-mannose glycoform preferentially samples conformations that are

234 This new quantitative glycoform profiling method with use of MALDI-TOF in posi

235 s that control prion replication and PrP(Sc) glycoform ratio.

236 n barrier that controls replication rate and glycoform ratios and has broad implications.

237 e cell surface and the mechanisms of altered glycoform related with HCC.

238 However, measurement of low abundant glycoforms remains challenging in complex samples like s

239 We also analyze structures for glycoforms representing those present in the nascent gly

240 osaccharide content analysis of this altered glycoform revealed an increase in glucosamine deposition

241 Capillary electrophoresis greatly improved glycoform separation for both released glycans and glyco

242 To achieve optimal glycoform separation, background electrolytes of low pH

243 The four glycoforms share a common core structure, and the differ

244 ho typically exhibit increased amounts of G0 glycoforms, showed increased MUC16 binding compared to u

245 targeted for the examination of the protein glycoforms, simplifying the analysis without sacrificing

246 ion sites but not glycosylation occupancy or glycoform stoichiometry.

247 tive glycopeptides that carried a variety of glycoform substitutions, each of which was linked throug

248 ammaRIIIa binding, compared to the truncated glycoforms, suggesting a role of IgG1 Fc N-glycan in opt

249 geted mode, it identified more site-specific glycoforms than the more commonly used data-dependent ac

250 ceptor-binding activity, and an azido-tagged glycoform that can be further transformed into other gly

251 oforms, including a fully sialylated (S2G2F) glycoform that may gain anti-inflammatory activity, a no

252 i-inflammatory activity, a nonfucosylated G2 glycoform that showed significantly enhanced FcgammaIIIa

253 IV synthesized polySia selectively on a NRP2 glycoform that was characterized by the presence of sial

254 s usually exist as mixtures of heterogeneous glycoforms that are difficult to separate in pure glycof

255 rent numbers of sialic acids but also intact glycoforms that differed by the number and extent of neu

256 By contrast, glycoforms that lacked core oligosaccharide modification

257 contain a decrease in afucosylated bisecting glycoforms that preferentially bind FcgammaRs.

258 utants as a chemically uniform (Man5GlcNAc2) glycoform, the individual effect of each mutation on Fcg

259 eins contain populations of subtly different glycoforms; therefore, with stricter orientation control

260 r weight of the S trimer (17% for the HEK293 glycoform) they shield approximately 40% of the protein

261 Here we found that this cancer-specific MUC1 glycoform, through engagement of Siglec-9, 'educated' my

262 The synthetic homogeneous Fc glycoforms thus provide a useful tool for elucidating ho

263 ansformed from mixtures of G0F, G1F, and G2F glycoforms to well-defined homogeneous glycoforms, inclu

264 he glycomic profile, not restricted to a few glycoforms, to differentiate samples from two different

265 The presence of a fully functional beta-glycoform together with the activity retained by these v

266 R) binding studies with the synthetic IgG-Fc glycoforms unambiguously proved that the presence of a b

267 on also increases the thermostability of CBM glycoforms up to 16 degrees C, and a mannose disaccharid

268 enerally limited in their ability to resolve glycoforms using mobile phases that are compatible with

269 We compared these isotype and N-glycoform variants with commercially available palivizum

270 king the naturally occurring APC-beta plasma glycoform was found to exhibit superior PAR1 proteolysis

271 Accordingly, the beta-L99F glycoform was fully activated by heparin.

272 ding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransfer

273 sequentially truncated high-mannose IgG1 Fc glycoforms, we found that the C'E loop and the Cgamma2-C

274 rofile of antibodies and HDX property of the glycoforms were also determined by accurate intact mass

275 These glycoforms were associated with enhanced Fc-mediated red

276 Because most relatives with abnormal IgA1 glycoforms were asymptomatic, additional cofactors must

277 Regarding the F(ab')2 domain, 8 glycoforms were detected and separated in three differen

278 Six non-fucosylated diantennary complex type glycoforms were detected on the Asn144-containing glycop

279 global snapshots of major cellular N-linked glycoforms were detected, including their tissue localiz

280 lycan heterogeneity as well as the ratios of glycoforms were determined at each site.

281 Thirteen distinct glycoforms were identified for the Asn340-containing tai

282 transplacental IgG transport, as certain Fc glycoforms were reported to be enriched in fetal circula

283 Mechanistically, CD43 glycoforms were unperturbed by peracetylated N-(3-acetyl

284 he peptides may lead to the misassignment of glycoforms when LC-MS/MS with electron-transfer dissocia

285 knockdown cell line was the pure Man5GlcNAc2 glycoform, whereas that produced from the FUT8-overexpre

286 We generated a panel of engineered ACE2 glycoforms which were analyzed by mass spectrometry to r

287 expression of only one major oligosaccharide glycoform, which lacked the terminal galactose residue a

288 IVIG's Fc glycans into a fully sialylated Fc glycoform, which may possess significantly enhanced anti

289 The technology gave rise to the concept of glycoforms, which allow diversification of a protein's p

290 g for 19.7% of Remicade and 13.2% of Remsima glycoforms, which translated into a 2-fold reduction in

291 under sialidase catalysis and the rituximab glycoform with a sialylated complex-type biantennary gly

292 ffinities for crystalline cellulose, and the glycoform with a single mannose at each of three positio

293 c regression analyses showed that the IgG-Fc glycoform with fucosylation and fully galactosylation wa

294 Single erythropoietin (EPO) glycoforms with defined mature oligosaccharide structure

295 d separation and analysis of not only intact glycoforms with different numbers of sialic acids but al

296 al of enabling access to native and designed glycoforms with site-selectivity and glycan homogeneity.

297 flow for quantitative profiling of IgA1 HR O-glycoforms with site-specific resolution will enable ide

298 Interestingly, the glycoforms with small glycans at each site displayed hig

299 IgA1 glycoforms with some galactose-deficient (Gd) HR O-glyca

300 d in the identification of over 60 different glycoforms with up to nine sialic acids.